[
    [
        {
            "time": "2018-03-15",
            "original_text": "Biogen And Eisai May Be At Odds In Alzheimer's — So What Now?",
            "features": {
                "keywords": [
                    "Biogen",
                    "Eisai",
                    "Alzheimer's",
                    "odds"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Biogen And Eisai May Be At Odds In Alzheimer's — So What Now?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal",
            "features": {
                "keywords": [
                    "Dicerna",
                    "Eli Lilly",
                    "licensing",
                    "research",
                    "deal"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "Dicerna's stock rockets after licensing, research collaboration with Eli Lilly",
            "features": {
                "keywords": [
                    "Dicerna",
                    "stock",
                    "licensing",
                    "research",
                    "collaboration",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dicerna's stock rockets after licensing, research collaboration with Eli Lilly",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "Eli Lilly makes bet on gene-silencing drug firm Dicerna",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "gene-silencing",
                    "drug",
                    "Dicerna"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly makes bet on gene-silencing drug firm Dicerna",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "Lilly and Dicerna Announce RNAi Licensing and Research Collaboration",
            "features": {
                "keywords": [
                    "Lilly",
                    "Dicerna",
                    "RNAi",
                    "licensing",
                    "research",
                    "collaboration"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly and Dicerna Announce RNAi Licensing and Research Collaboration",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "Drug giant Lilly backs Cambridge's Dicerna in $200M deal",
            "features": {
                "keywords": [
                    "Lilly",
                    "Dicerna",
                    "Cambridge",
                    "deal"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Drug giant Lilly backs Cambridge's Dicerna in $200M deal",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "Dicerna Stock Surges On RNAi Deal With Lilly",
            "features": {
                "keywords": [
                    "Dicerna",
                    "Stock",
                    "RNAi",
                    "Deal",
                    "Lilly"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dicerna Stock Surges On RNAi Deal With Lilly",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "[$$] Follow the FDA’s Self-Interest",
            "features": {
                "keywords": [
                    "FDA",
                    "self-interest"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "regulatory",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[$$] Follow the FDA’s Self-Interest",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]